Neoplasms

Symptoms and General Pathology

All Conditions

Neoplasm Metastasis

Neoplastic Processes

Antineoplastic Agents

All Drugs and Chemicals

Gastrointestinal Agents

Anticoagulants

Anti-Infective Agents

Micronutrients

Hematinics

Other Dietary Supplements

Vitamins

Carboplatin

Pemetrexed

Ranitidine

Ranitidine bismuth citrate

Bismuth

Citric Acid

Sodium Citrate

Bismuth tripotassium dicitrate

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antacids

Anti-Ulcer Agents

Histamine

Histamine H2 Antagonists

Histamine phosphate

Histamine Antagonists

Neurotransmitter Agents

Citrate

Folinic Acid

Folate

Vitamin B9

Part A, Cycle 1 (28 days): Intravenous doses of LY2090314 starting at 10 milligram (mg) were given on Day 1 followed by 10 mg LY2090314, 500 milligram per square meter (mg/m\^2) pemetrexed (intravenous dose), and 5 or 6 area under the concentration-time curve (AUC) intravenous dose of carboplatin on Day 8.

Part A, Cycle 2 (21 days): Pemetrexed and carboplatin given on Day 1 at the same dose administered in Cycle 1.

Part A, Cycle 3 (21 days) and beyond: LY2090314, Pemetrexed and carboplatin were given on Day 1 at the same dose administered in Cycle 1. LY2090314 doses were escalated until the maximum tolerated dose (MTD) was reached.

Part B: Dose determined in Part A was administered. Participants were allowed to continue the combination treatment if they were receiving therapeutic benefit until they fulfilled one of the criteria for discontinuation.

LY2090314

pemetrexed

Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.

ranitidine

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

The purpose of this study is to determine a recommended Phase 2 dose and dosing regimen of LY2090314 in combination with pemetrexed and carboplatin in patients with advanced/metastatic cancer. Part A of this study will consist of dose escalation of the study regimen, and Part B will consist of an expanded cohort to confirm the dose provided from Part A.

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin

Recommended Phase 2 MTD was determined, when a dose limiting toxicity (DLT) occurred in 1 of 3 participants, the cohort was to be expanded to 6 participants. If a DLT occurred in 2 or more participants, accrual to the cohort was stopped, as the MTD was exceeded. A DLT was defined as an adverse event (AE) occurring in Cycle 1 (28 days) that was possibly related to study drug and met 1 of the following criteria: According to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0, ≥Grade 3 nonhematologic toxicity (except for nausea/vomiting without maximal symptomatic/prophylactic treatment) possibly or likely related to the study medication;CTCAE Grade 4 hematological toxicity of \>5 days duration; Febrile neutropenia; CTCAE Grade 4 thrombocytopenia; CTCAE ≥Grade 2 thrombocytopenia plus bleeding; CTCAE ≥Grade 3 prolonged QTc interval.

AUC0-∞ was calculated from the area under the concentration versus time curve from time 0 to infinity of LY2090314 when administered alone.

AUC0-∞ was calculated from the area under the concentration versus time curves of LY2090314 from time zero to infinity when coadministered with Pem and Carb.

Best overall observed tumor response at any point during the study until disease progression/recurrence defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as at least 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.

AUC0-∞ was calculated from the area under the concentration versus time curves of Pem given as a single dose with Carb (doublet therapy) and when co-administered with Carb and LY2090314 (triplet therapy).

Cmax of Pem given as a single dose with Carb (doublet therapy) and when coadministered with Carb and LY2090314 (triplet therapy).

AUC0-∞ of free Carb was calculated from the area under the concentration versus time curves of Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy).

Cmax of free Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy).

PD change from baseline to endpoint (up to Cycle 9) in β-catenin levels in peripheral blood mononuclear cells (PBMCs) following the administration of LY2090314 given alone and in combination with Pem and Carb. This outcome measure was not analyzed due to insufficient data.

Eli Lilly and Company

* Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 administered by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion followed by 10 mg LY2090314 administered by intravenous infusion.

LY 10/Carb 5/Pem 500 (Cohort 1)

* Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.

LY 10/Carb 6/Pem 500 (Cohort 2)

* Cycle 1 Day 1 of 28 day cycle: 20 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.

LY 20/Carb 6/Pem 500 (Cohort 3)

* Cycle 1 Day 1 of 28 day cycle: 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.

LY 40/Carb 6/Pem 500 (Cohort 4)

* Cycle 1 Day 1 of 28 day cycle: 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.

LY 80/Carb 6/Pem 500 (Cohort 5)

* Cycle 1 Day 1 of 28 day cycle: 120 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.

LY 120/Carb 6/Pem 500 (Cohort 6)

* Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion.

Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

LY 80/Carb 6/Pem 500 + R50 (Cohort 7)

* Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion.

Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

LY 60/Carb 6/Pem 500 + R50 (Cohort 8)

* Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40mmg LY2090314 40 mg by intravenous infusion.
* Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion.

Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

LY 40/Carb 6/Pem 500 + R50 (Cohort 9)

* Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

Total

Age, Continuous

Sex: Female, Male

African

Caucasian

Hispanic

Race/Ethnicity, Customized

United States

Region of Enrollment

Body Surface Area

ECOG - Classified participants according to their functional impairment. Scores ranged from 0 to 5: 0=Fully Active, No Restrictions; 1=Ambulatory, Able to Perform Light Work Activities (for example, light house work), Restricted Strenuous Activity; 2=Ambulatory, All Self Care, No Work Activities; 3=Partially Confined to Bed (\>50% of waking hours), Limited Self Care; 4=Completely Disabled, Totally Bedridden; 5=Death

Eastern Cooperative Oncology Group (ECOG) performance

Cytological

Histopathological

Basis of Diagnosis

Mesothelioma

Non-small cell lung carcinoma (NSCLC)

Leimyosarcoma

Esophagus

Lung adenocarcinoma

Rectum

Small cell lung carcinoma (SCLC)

Gastric

Head and neck

Adenocarcinoma not otherwise specified (NOS)

Colon

Breast

Pancreas

Cancer NOS

Gall bladder

Thymoma

Adenoid

Bile duct

Initial Pathological Tumor Diagnosis

All randomized participants who received at least 1 dose of study drug.

Chief Medical Officer

Cycle 1 (28 days)

Cohorts 1 to 3

* Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion.

Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion.

-Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.

LY2090314/Pemetrexed/Carboplatin

Safety population: all participants who have received at least 1 dose of the study drug.

Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])

* Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 (Cohort 1) or AUC 6 (Cohort 2) mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 (Cohort 1) or AUC 6 (Cohort 2) mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.

LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)

* Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion.

Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous.

Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

LY 40/Carb 6/Pem 500 (Cohorts 4 and 9)

* Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.

Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous.

Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

LY 80/Carb 6/Pem 500 (Cohorts 5 and 7)

* Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

All participants who received at least 1 dose of LY2090314 and had evaluable AUC0-∞ data, excluding 2 participants (1 in dose groups LY80 and 1 in dose group LY120) who received the wrong dose of LY2090314.

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314

Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.

Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous.

Based on I2H-MC-JWYa Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.

Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

All participants who received at least 1 dose LY2090314 coadministered with Pem and Carb and had enough samples to allow estimation of AUC0-∞ parameters excluding 2 participants (1 in dose groups LY80 and 1 in dose group LY120) who received the incorrect dose of LY2090314.

PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

* Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by LY2090314 20 mg by intravenous infusion.

Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion.

Cohort 9, LY2090314 pretreated with 50 mg ranitidine IV. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

LY 40/Carb 6/Pem 500 (Cohorts 4 and 9 )

* Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.

Cohort 7, LY2090314 pretreated with 50 mg ranitidine IV.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

LY 80/Carb 6/Pem 500 (Cohorts 5 and 7

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by IV infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

All participants who received at least 1 dose of LY2090314 and had evaluable AUC0-∞ data, excluding 2 participants (1 in dose groups LY80 and 1 in dose group LY120) who received the incorrect dose of LY2090314.

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314

Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.

Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion.

Based on I2H-MC_JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

Unknown (discontinued before response assessment)

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

Analysis population: all participants who received at least 1 dose of study drug and had tumor response assessment.

Number of Participants With Best Overall Tumor Response

Pem with Carb

* Participants in Cohorts 1, 2 and 3 were administered 500 mg/m\^2 Pem and AUC 5 or AUC 6 mg/mL \* min Carb on Cycle 1, Day 8 of 28-day cycle by intravenous infusion.
* Participants in Cohorts 4 through 9 were administered 500 mg/m\^2 Pem and AUC 6 mg/mL \* min Carb by intravenous infusion on Cycle 2 Day 1 of 21-day cycle

Pemetrexed (Doublet Therapy)

Pem with Carb and LY2090314

* Participants in Cohorts 1, 2 and 3 were administered 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg up to 20 mg LY2090314 by intravenous infusion on Cycle 2 up to Cycle 10: Day 1 of 21-day cycle.
* Participants in Cohorts 4 through 9 were administered 500 mg/m\^2 Pem and AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg up to 120 mg of LY2090314 by intravenous infusion on Cycle 1, Day 8 of 28-day cycle and Cycle 3 up to Cycle 10: Day 1 of 21-day cycle.

Based on I2H-MC-JWYA Protocol Amendment (D) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain to participants in Cohorts 7, 8 and 9.

Pemetrexed (Triplet Therapy)

All participants who were treated with Pem and Carb (doublet therapy) or who were treated with Pem, Carb and LY2090314 (triplet therapy) and had evaluable AUC0-∞ Pem data.

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)

Pem with Carb and LY2090317

* Participants in Cohorts 1, 2 and 3 were administered 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg up to 20 mg LY2090314 by intravenous infusion on Cycle 2 up to Cycle 10: Day 1 of 21-day cycle.
* Participants in Cohorts 4 through 9 were administered 500 mg/m\^2 Pem and AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg up to 120 mg of LY2090314 by intravenous infusion on Cycle 1, Day 8 of 28-day cycle and Cycle 3 up to Cycle 10: Day 1 of 21-day cycle.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain to participants in Cohorts 7, 8 and 9.

All participants who were treated with Pem and Carb (doublet therapy) or who were treated with Pem, Carb and LY2090314 (triplet therapy) and had evaluable Cmax Pem data.

PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)

Carb and Pem

* Participants in Cohorts 1, 2 and 3 were administered 500 mg/m\^2 Pem and AUC 5 or AUC 6 mg/mL \* min Carb on Cycle 1, Day 8 of 28-day cycle by intravenous infusion.
* Participants in Cohorts 4 through 9 were administered 500 mg/m\^2 Pem and AUC 6 mg/mL \* min Carb by intravenous infusion on Cycle 2 Day 1 of 21-day cycle

Carboplatin (Doublet Therapy)

Carb with Pem and LY2090314

* Participants in Cohorts 1, 2 and 3 were administered 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg up to 20 mg LY2090314 by intravenous infusion on Cycle 2 up to Cycle 9: Day 1 of 21-day cycle.
* Participants in Cohorts 4 through 9 were administered 500 mg/m\^2 Pem and AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg up to 120 mg of LY2090314 by intravenous infusion on Cycle 1, Day 8 of 28-day cycle and Cycle 3 up to Cycle 9: Day 1 of 21-day cycle.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain to participants in Cohorts 7, 8 and 9.

Carboplatin (Triplet Therapy)

All participants who were treated with Pem and Carb (doublet therapy) or Pem, Carb and LY2090314 (triplet therapy) and who had evaluable Carb AUC0-∞ data.

PK Parameter: AUC0-∞ of Free Carboplatin (Carb)

Carb and Pem with LY2090314

* Participants in Cohorts 1, 2 and 3 were administered 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg up to 20 mg LY2090314 by intravenous infusion on Cycle 2 up to Cycle 9: Day 1 of 21-day cycle.
* Participants in Cohorts 4 through 9 were administered 500 mg/m\^2 Pem and AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg up to 120 mg of LY2090314 by intravenous infusion on Cycle 1, Day 8 of 28-day cycle and Cycle 3 up to Cycle 10: Day 1 of 21-day cycle.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain to participants in Cohorts 7, 8 and 9.

All participants who were treated with Pem and Carb (doublet therapy) or who were treated with Pem, Carb and LY2090314 (triplet therapy) and had evaluable Carb Cmax data.

PK Parameter: Cmax of Free Carboplatin

* Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 mg/mL \* min Carb by IV infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by IV infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28 -ay cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 mg by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine IV pretreatment and 60 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

There was insufficient data from participants who received at least 1 dose of LY2090314 to perform β-catenin modeling, thus zero participants were analyzed.

Pharmacodynamic (PD) Changes in Beta-Catenin (β-catenin)

* Cycle 1 Day 1 of 28-day cycle: 10 milligrams (mg) LY2090314 (LY) administered by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 milligrams per meter squared (mg/m\^2) pemetrexed (Pem) administered by intravenous infusion followed by Area Under the Time Curve (AUC) 5 milligrams per milliliter times minutes (mg/mL \* min) carboplatin (Carb) administered by intravenous infusion.
* Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion followed by 10 mg LY2090314 administered by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion.
* Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 and beyond: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.

* Cycle 1 Day 1 of 28 -ay cycle: 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 up and beyond: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion

* Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion.
* Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.

LY 120/Carb 6/Pem 500 -(Cohort 6)

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine (R50) intravenous, 80 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem IV infusion.
* Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by IV infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

* Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion.
* Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion.
* Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion.
* Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine IV pretreatment and 40 mg LY2090314 intravenous infusion.

Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.

Spots Global Cancer Trial Database for A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial